A quick walk through the last 20 years of biotech investing in Europe and a snapshot of the state of the...
Analysis of European Biotech Companies on the Stock Markets
The BIOCOM report “Analysis of European Biotech Companies on the Stock Markets: US vs Europe” provides a complete overview of the current European public biotech sector. Ever since 2012, it covers all IPOs, follow-on financings, and secondary listings on all major stock market centres in Europe, as well as on Nasdaq.
Download the report 2018/2 published in the European Biotechnology Magazine (PDF)
Do you want to know more? Are you ready to become part of the European biotech picture? Contact us now:
Latest Updates
Biotech stock markets are still appreciated by investors. Whereas the number of IPOs significantly decreased...
Due to its broad spectrum of investors, the US Nasdaq continues to be an attractive stock market for European...
An IPO is a veritable option for funding biotech companies. This has been proven by the successful listing of...
For private investors, Nasdaq rather than Europe is often the preferred place for a biotech IPO, says Karl...
After a healthy reset in 2016, biotech stock markets experienced a new wave of optimism with increased volumes...